171 related articles for article (PubMed ID: 33263441)
1. Development of molecular intervention strategies for B-cell lymphoma.
Zhou W; Chen W
Expert Rev Hematol; 2021 Feb; 14(2):241-252. PubMed ID: 33263441
[TBL] [Abstract][Full Text] [Related]
2. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Makita S; Hosoba R; Tobinai K
Expert Opin Drug Saf; 2020 Sep; 19(9):1105-1120. PubMed ID: 32715803
[TBL] [Abstract][Full Text] [Related]
3. The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.
Wang H; Zhang W; Yang J; Zhou K
Hematol Oncol; 2021 Dec; 39(5):605-615. PubMed ID: 34651869
[TBL] [Abstract][Full Text] [Related]
4. Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.
Manji F; Puckrin R; Stewart DA
Expert Opin Pharmacother; 2021 Aug; 22(11):1417-1427. PubMed ID: 33711241
[No Abstract] [Full Text] [Related]
5. Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.
Chung C
J Oncol Pharm Pract; 2020 Jun; 26(4):943-966. PubMed ID: 31964218
[TBL] [Abstract][Full Text] [Related]
6. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
7. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.
de Groen RAL; Schrader AMR; Kersten MJ; Pals ST; Vermaat JSP
Haematologica; 2019 Dec; 104(12):2337-2348. PubMed ID: 31699794
[TBL] [Abstract][Full Text] [Related]
8. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.
Kapoor I; Bodo J; Hill BT; Hsi ED; Almasan A
Cell Death Dis; 2020 Nov; 11(11):941. PubMed ID: 33139702
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
10. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
12. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Zain J; O'Connor OA
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
[TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A
Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268
[TBL] [Abstract][Full Text] [Related]
14. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
15. Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.
Santos Gda C; Saieg MA; Ko HM; Geddie WR; Boerner SL; Craddock KJ; Crump M; Bailey D
Cancer Cytopathol; 2015 Jul; 123(7):413-20. PubMed ID: 25807917
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough therapies in B-cell non-Hodgkin lymphoma.
Cheah CY; Fowler NH; Wang ML
Ann Oncol; 2016 May; 27(5):778-87. PubMed ID: 26802148
[TBL] [Abstract][Full Text] [Related]
17. Targeting BCL-2 in B-cell lymphomas.
Davids MS
Blood; 2017 Aug; 130(9):1081-1088. PubMed ID: 28724540
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 Inhibitors, Present and Future.
Ryan CE; Davids MS
Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
[TBL] [Abstract][Full Text] [Related]
20. New drugs for aggressive B-cell and T-cell lymphomas.
Murawski N; Pfreundschuh M
Lancet Oncol; 2010 Nov; 11(11):1074-85. PubMed ID: 21051020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
